Key result
Valsartan in Chinese adults with essential hypertension and albuminuria achieved a 17.8% blood pressure control rate at 12 weeks and significantly reduced blood pressure from baseline (P<0.001).
Why the study?
The efficacy and safety of valsartan in reducing blood pressure and albuminuria in Chinese adult patients with essential hypertension and albuminuria needed evaluation.
Does valsartan reduce blood pressure and albuminuria in Chinese adult patients with essential hypertension and albuminuria?
Observational (n=1,180)
Open-label
Yes
Does valsartan reduce blood pressure and albuminuria in Chinese adult patients with essential hypertension and albuminuria?
Valsartan effectively reduces blood pressure and albuminuria in Chinese patients with essential hypertension, with a more pronounced effect on albuminuria in diabetic patients.
Answers are grounded in this paper and cite their sources.
Valsartan was associated with BP and albuminuria reductions in this Chinese cohort; leaves open whether it improves hard renal outcomes versus other ARBs.
OBJECTIVE: To evaluate the efficacy and safety of 80 or 160 mg/day valsartan in Chinese adult patients with essential hypertension and albuminuria. METHODS: A multicenter prospective open-label observational study was conducted. Adult hypertensive patients with albuminuria were treated with 80 or 160 mg/day valsartan. Blood pressure (BP) was recorded at weeks 4, 8 and 12. Albuminuria was selectively measured at week 12. RESULTS: The intent-to-treat (ITT) population included 1180 patients. Mean sitting systolic BP (MSSBP) and diastolic BP (MSDBP) at baseline was 153.5 [14.41] (mean [SD]) and 88.2 [11.99] (mean [SD]) mmHg. MSSBP and MSDBP at week 4 (mean [SD]: 139.1 [12.02] and 82.2 [8.54] mmHg), week 8 (mean [SD]: 135.3 [10.46] and 80.2 [7.55] mmHg) and week 12 (mean [SD]: 132.1 [9.80] and 78.1 [6.88] mmHg) were significantly lower than baseline (p < 0.001). The BP control rate of ITT patients at week 12 was 17.8%. Diabetic patients exhibited lower BP control rate than non-diabetic patients (14.0 vs. 22.4%, p < 0.001). A total of 904 patients had albuminuria assessed at week 12. UACR and UAER at week 12 were lower compared with baseline (p < 0.05). In all, 171 patients (18.9%) returned to normal albuminuria and albuminuria normalization percentage in diabetic patients exceeded that of non-diabetic patients (26.3 vs. 12.1%, p < 0.001). Albuminuria declined by more than 50% in 340 patients (37.6%) and more diabetic patients exhibited such decline in albuminuria than non-diabetic patients (41.7 vs. 33.8%, p < 0.05). No serious drug-related adverse effects (AEs) were observed. LIMITATIONS: Prior antihypertensive treatment before valsartan administration may interfere with the efficacy of subsequent treatment. The discrepancy between 80 and 160 mg may affect patient outcomes and occurrence of AEs. CONCLUSIONS: Valsartan can safely and effectively reduce BP and albuminuria in Chinese adult patients with essential hypertension and albuminuria. Valsartan has the more dramatic effect on albuminuria in diabetic patients than non-diabetic patients.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2012) conducted an observational in essential hypertension and albuminuria (n=1,180). Valsartan was evaluated on Blood pressure control rate at week 12. Valsartan in Chinese adults with essential hypertension and albuminuria achieved a 17.8% blood pressure control rate at 12 weeks and significantly reduced blood pressure from baseline (P<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: